On the other hand, the reason for PD-1/PD-L1 based immunotherapy has achieved promising results in some advanced cancers might be owing to the therapy has targeted CSCs in these cancers, because advanced tumour would generally contain more CSCs. This evidence concerns the gene PDCD1 and neoplasm.